Credit and interest ratesnegative · 4 filings
“Interest expense was $2.8 million and $3.0 million for the three months ended March 31, 2026 and 2025, respectively, reflecting a decrease of $0.2 million year-over-year.”10-Q · May 5, 2026 ↗
Ocular Therapeutix, Inc.
OCUL
Market read
Ocular Therapeutix, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 18 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
Company-1.1% todayVolume comparison unavailable
Market group0 of 18 activeBiotech and Energy · unavailable
Disclosed network0 of 3 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- OCUL's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if OCUL's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 18 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- OCUL's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods9
Price observations320
Usable filing statements90
Verified relationships3
Evidence supporting the case
No qualifying supportive evidence was identified.
Evidence challenging the case
- Latest annual revenue changed -18.5% year over year.
- Operating margin changed -250.2 percentage points in the latest annual period.
- Net margin changed -208.2 percentage points in the latest annual period.
- Diluted shares increased 18.3% in the latest annual period.
- Credit and interest rates has repeated adverse evidence across 4 filings.
- Product pipeline and R&D has repeated adverse evidence across 4 filings.
Questions before a position
- EV/sales is 169% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 11, 2026
10.506m-4.4%12m-16.2%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$43.5M+150.1%$-0.98+35.2%
2022-12-31$51.5M+18.3%$-0.97+0.6%
2023-12-31$58.4M+13.5%$-1.02+3.6%
2024-12-31$63.7M+9.0%$-1.22—
2025-12-31$52.0M-18.5%$-1.42+18.3%
What management says matters
Persistent and emerging business drivers
Product pipeline and R&Dnegative · 4 filings
“Our net loss was primarily attributed to operating expenses of $74.6 million, which we incurred primarily for research and development activities, selling and marketing activities, and general and administrative activities, partially offset by $10.7 million o…”10-Q · May 5, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 37.8× · EV/sales 23.6×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
10.50-1.1% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for OCUL. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for OCUL. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind OCUL
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
JEFJefferies Financial Group Inc.partnerNov 4, 2025 ▾
“In August 2021, we entered into an Open Market Sale Agreement, or the 2021 Sales Agreement, with Jefferies LLC, or Jefferies, under which we may offer and sell shares of our common stock from time to time through Jefferies, acting as agent.”
JEFJefferies Financial Group Inc.lenderMay 5, 2026 ▾
“In August 2021, we entered into an Open Market Sale Agreement, or the 2021 Sales Agreement, with Jefferies LLC, or Jefferies, under which we may offer and sell shares of our common stock from time to time through Jefferies, acting as agent.”
Depended on by
FDMT4D Molecular Therapeutics, Inc.competitorMar 18, 2026 ▾
“We also face competition from late-stage sustained release VEGF receptor tyrosine kinase 11 inhibitor programs at EyePoint Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 3 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
OCUL is currently a Follower in the organic co-movement group Biotech and Energy. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for OCUL; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.